Spondyloarthritis

Drug-induced lupus resolves after anti-TNF switch

08/02/2010 | Australian rheumatologists have reported the third known case of infliximab-related lupus which resolved after drug cessation and did not recur on switching to another TNF inhibitor. 1 comment

Psychological approach alters pain perception in fibromyalgia

08/02/2010 | Psychological therapy may alter pain processing in the spinal cord and potentially reduce the symptoms of fibromyalgia, a new study has concluded.

RCTs underestimate comorbidity in AS patients

01/02/2010 | Australian patients with ankylosing spondylitis who are starting biological therapy in routine clinical practice have more comorbidities than those who have met the inclusion criteria for clinical trials, Australian rheumatologists say.

Severe infection risks with anti TNF-alpha treatment

07/09/2009 | Doctors from Western Australia have presented a case report that they say highlights the potentially life-threatening infections that can be masked in patients immunocompromised by anti TNF-alpha treatment.

Infliximab reduces disease activity in early sacrolitis

05/04/2009 | Researchers have demonstrated the efficacy - both clinically and on MRI - of anti-TNF biologic therapy in patients with preradiographic aches in spondylarthropathy.

MRI helps to predict anti-TNF response in AS

18/09/2008 | New findings indicate that spinal inflammation detected by magnetic resonance imaging may predict the response to tumour necrosis factor therapy in patients with ankylosing spondylitis. Source: Rudwaleit, M. Annals of the Rheumatic Diseases 2008; 67: 1276-1281.

Long-term data supports adalimumab in AS

01/09/2008 | New on-line first findings indicate that adalimumab is effective in reducing the signs and symptoms of ankylosing spondylitis for up to two years. Source: van der Heijde, D. et al. Annals of the Rheumatic Diseases 2008; Online First. Volume and edition to be announced.

Images in clinical medicine: Ankylosing spondylitis

25/07/2008 | This week's clinical image in the New England Journal of Medicine is of the spine of a 66-year old man with ankylosing spondylitis. A progressive reduction of global spine movement for more than two decades eventually resulted in complete spinal immobility.

Anti-TNF agents associated with changed body composition in spondyloarthropathies

27/06/2008 | New findings link the use of anti-TNF agents in patients with ankylosing spondylitis to a significant increase in body weight, mostly due to a gain in fat mass and increased bone mineral density. Source: Briot, K. et al. Journal of Rheumatology 2008; 35: 855-861.

Inflammatory biomarkers may aid patient selection in Ankylosing Spondylitis

11/04/2008 | Significant reductions in disease activity biomarkers following infliximab therapy may help predict patients who are likely to respond, according to a recent study. Source: Visvanathan, S. Annals of the Rheumatic Diseases 2008; 67: 511-517.